Investors have shown a lack of confidence in Tianzhihang's plan to acquire Shanghai MicroPort Orthopedics, a deal often described as a "snake swallowing an elephant." The stock fell 8.85% on its first day back from a trading halt, closing at 17.4 yuan per share.
Three key issues are driving this skepticism. First, the target company carries high debt and continues to post losses, raising concerns about the financial health of the combined entity. Second, the expected synergy between robotics and implants is questionable given the performance of MicroPort's own orthopedic robot. Third, the competitive landscape is fierce, with established players already dominating the market.
Why are investors so concerned about this acquisition?
Tianzhihang plans to issue shares to acquire a 62% stake in Shanghai MicroPort Orthopedics, a company with revenues several times larger than its own. While Tianzhihang's 2024 revenue was 179 million yuan, the target's revenue was 1.669 billion yuan, roughly nine times larger. Despite this scale, the target has been operating at a net loss, which has been widening, and its debt-to-asset ratio soared to 86% in the first quarter of this year. In contrast, Tianzhihang's own debt ratio is below 30% with cash reserves under 200 million yuan. Analysts worry that consolidating this high-debt, loss-making asset could severely drag down the acquirer's financial statements.
Is the "robot plus implant" synergy real?
Tianzhihang argues the deal will create a powerful "robot plus implant" combination, accelerating its global expansion. However, the target company is being sold by MicroPort, which already owns the SkyWalker orthopedic surgical robot. This robot's overseas sales have been heavily dependent on distribution agreements with its parent company. Despite this, the target's revenue actually declined by over 5% in 2025, calling into question the practical synergies between the robot and implant businesses within the MicroPort ecosystem.
Can Tianzhihang break into a crowded global market?
The global orthopedic implant market is dominated by giants like Johnson & Johnson, Stryker, Medtronic, and Zimmer Biomet, which together control about 70% of the market. Stryker's Mako robot has already successfully executed the "razor-blade" business model Tianzhihang is aiming for, with over 3,000 units installed globally and a track record of driving its own implant sales. Tianzhihang admits the overseas market is highly competitive. The target company has only recently filed a 510(k) application with the FDA for its surgical robot, and the timeline for approval is uncertain. Failure to secure timely approval would severely delay Tianzhihang's entry into the US market and hinder its international growth strategy.